Critical evaluation of the MitraClip system in the management of mitral regurgitation
Standard
Critical evaluation of the MitraClip system in the management of mitral regurgitation. / Deuschl, Florian; Schofer, Niklas; Lubos, Edith; Blankenberg, Stefan; Schäfer, Ulrich.
In: VASC HEALTH RISK MAN, Vol. 12, 2016, p. 1-8.Research output: SCORING: Contribution to journal › SCORING: Review article › Research
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Critical evaluation of the MitraClip system in the management of mitral regurgitation
AU - Deuschl, Florian
AU - Schofer, Niklas
AU - Lubos, Edith
AU - Blankenberg, Stefan
AU - Schäfer, Ulrich
PY - 2016
Y1 - 2016
N2 - The MitraClip (MC) system is a device for percutaneous, transseptal edge-to-edge reconstruction of the mitral valve (MV) in patients with severe mitral regurgitation (MR) not eligible for surgery. Recently, a number of studies have underlined the therapeutic benefit of the MC system for patients with extreme and high risk for MV surgery suffering from either degenerative or functional MR. The MC procedure shows negligible intraprocedural mortality, low periprocedural complication rates, and a significant reduction in MR, as well as an improvement in functional capacity and most importantly quality of life. Presently, the MC system has become an additional interventional tool in the concert of surgical methods. It hereby enlarges the spectrum of MV repair for the Heart Team. Lately, many reviews focused on the MC system. The current review describes the developments in the treatment of MR with the MC system.
AB - The MitraClip (MC) system is a device for percutaneous, transseptal edge-to-edge reconstruction of the mitral valve (MV) in patients with severe mitral regurgitation (MR) not eligible for surgery. Recently, a number of studies have underlined the therapeutic benefit of the MC system for patients with extreme and high risk for MV surgery suffering from either degenerative or functional MR. The MC procedure shows negligible intraprocedural mortality, low periprocedural complication rates, and a significant reduction in MR, as well as an improvement in functional capacity and most importantly quality of life. Presently, the MC system has become an additional interventional tool in the concert of surgical methods. It hereby enlarges the spectrum of MV repair for the Heart Team. Lately, many reviews focused on the MC system. The current review describes the developments in the treatment of MR with the MC system.
KW - Cardiac Catheterization/adverse effects
KW - Equipment Design
KW - Humans
KW - Mitral Valve/physiopathology
KW - Mitral Valve Insufficiency/diagnosis
KW - Quality of Life
KW - Recovery of Function
KW - Risk Factors
KW - Severity of Illness Index
KW - Treatment Outcome
U2 - 10.2147/VHRM.S65185
DO - 10.2147/VHRM.S65185
M3 - SCORING: Review article
C2 - 26811687
VL - 12
SP - 1
EP - 8
JO - VASC HEALTH RISK MAN
JF - VASC HEALTH RISK MAN
SN - 1176-6344
ER -